V1RB4 Inhibitors
V1RB4 inhibitors are a class of chemical compounds designed to selectively bind to and inhibit the activity of a specific type of receptor known as V1RB4. This receptor belongs to a larger family of receptors that play a crucial role in the transmission of certain signals within biological systems. These inhibitors are characterized by their ability to interact with the V1RB4 receptor's active site, blocking its natural ligand from binding and thus preventing the subsequent signal transduction that normally follows receptor activation. The precise action of V1RB4 inhibitors involves complex molecular interactions, where the shape, charge, and hydrophobic or hydrophilic nature of the inhibitor molecules are finely tuned to fit into the receptor binding site with high specificity.
The design and development of V1RB4 inhibitors require a deep understanding of molecular biology and chemistry, particularly the structural aspects of the V1RB4 receptor. Researchers utilize various techniques such as X-ray crystallography, computer-aided design, and iterative synthesis to elucidate the receptor's structure and to craft molecules that can effectively interact with it. The structural complementarity between the V1RB4 inhibitors and the receptor ensures that these compounds can effectively compete with the natural ligands of the receptor. This interaction is typically reversible, allowing the inhibitors to dissociate from the receptor, which is an important consideration in the development of such compounds. The specificity of V1RB4 inhibitors is paramount, as off-target effects can lead to unintended interactions with other receptor types, which is why the chemical structure of these inhibitors is often highly refined to minimize such occurrences.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palmitoylethanolamide | 544-31-0 | sc-202754 sc-202754A sc-202754B sc-202754C sc-202754D | 10 mg 50 mg 500 mg 1 g 10 g | $80.00 $243.00 $2091.00 $3339.00 $16657.00 | ||
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that binds to a receptor in the cell nucleus (peroxisome proliferator-activated receptor-alpha). PEA down-regulates mast cell activation, which could indirectly inhibit V1RB4 activity by reducing the release of neurotransmitters that may modulate this receptor's signaling. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine activates adenosine receptors, which can have an inhibitory effect on neurotransmission. Through the activation of A1 receptors, adenosine can decrease cyclic AMP levels, which might reduce the activity of V1RB4 by altering the signaling environment in which V1RB4 operates. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor type 1 (AT1) antagonist. By blocking AT1 receptors, losartan may reduce angiotensin II-induced vasoconstriction and subsequently could alter V1RB4 signaling in vascular tissues. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is a polyphenol that activates sirtuin 1 (SIRT1), which is involved in deacetylating transcription factors and histone proteins. Activation of SIRT1 could lead to altered gene expression profiles that indirectly downregulate V1RB4 activity. | ||||||
Rimonabant | 168273-06-1 | sc-205491 sc-205491A | 5 mg 10 mg | $73.00 $163.00 | 15 | |
Rimonabant is a selective cannabinoid receptor type 1 (CB1) antagonist. By antagonizing CB1, rimonabant may decrease endocannabinoid signaling, potentially affecting G-protein coupled receptor mediated pathways and indirectly inhibiting V1RB4 activity. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic receptor antagonist. By blocking beta-adrenergic receptors, it can decrease adrenergic signaling, which might indirectly influence V1RB4 activity if V1RB4 is part of adrenergic-responsive networks. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Ondansetron is a serotonin 5-HT3 receptor antagonist. By inhibiting 5-HT3 receptors, ondansetron could reduce serotonin signaling, which may indirectly affect V1RB4 activity if V1RB4 signaling is modulated by serotonin levels. | ||||||
Memantine hydrochloride | 41100-52-1 | sc-203628 | 50 mg | $69.00 | 4 | |
Memantine is an NMDA receptor antagonist. By blocking NMDA receptor activity, it can modulate glutamatergic signaling, which might indirectly reduce V1RB4 activity if V1RB4 is influenced by glutamate neurotransmission. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Lidocaine is a sodium channel blocker that inhibits action potential propagation in neurons. This could lead to a reduced neuronal activity and, consequently, a decrease in neurotransmitter release that could indirectly inhibit V1RB4 signaling if V1RB4 is modulated by neuronal activity. | ||||||
(±)-Baclofen | 1134-47-0 | sc-200464 sc-200464A | 1 g 5 g | $56.00 $258.00 | ||
Baclofen is a GABAB receptor agonist. By activating GABAB receptors, baclofen can inhibit neurotransmitter release, including neurotransmitters that may regulate V1RB4 activity, thus providing an indirect means of inhibiting V1RB4 signaling. | ||||||